Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
Shanghai Shen Lian Biomedical Corp (688098) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.015x
Based on the latest financial reports, Shanghai Shen Lian Biomedical Corp (688098) has a cash flow conversion efficiency ratio of 0.015x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.52 Million) by net assets (CN¥1.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Shen Lian Biomedical Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Shanghai Shen Lian Biomedical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shanghai Shen Lian Biomedical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shen Lian Biomedical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andretti Acquisition Corp. II Unit
NASDAQ:POLEU
|
-0.001x |
|
Xinjiang Hejin Holding Co Ltd
SHE:000633
|
0.067x |
|
Bumitama Agri Ltd
F:2BU
|
0.030x |
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
-0.004x |
|
Bakkavor Group plc
PINK:BKKVF
|
0.129x |
|
Quadient SA
PA:QDT
|
0.032x |
|
Team17 Group plc
OTCGREY:TSVNF
|
0.033x |
|
Boston Omaha Corp
NYSE:BOC
|
0.009x |
Annual Cash Flow Conversion Efficiency for Shanghai Shen Lian Biomedical Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Shen Lian Biomedical Corp from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.43 Billion | CN¥89.36 Million | 0.063x | +2579.52% |
| 2023-12-31 | CN¥1.51 Billion | CN¥3.53 Million | 0.002x | -61.47% |
| 2022-12-31 | CN¥1.50 Billion | CN¥9.09 Million | 0.006x | -90.08% |
| 2021-12-31 | CN¥1.47 Billion | CN¥90.12 Million | 0.061x | -23.54% |
| 2020-12-31 | CN¥1.40 Billion | CN¥111.73 Million | 0.080x | +90.53% |
| 2019-12-31 | CN¥1.28 Billion | CN¥53.81 Million | 0.042x | -71.15% |
| 2018-12-31 | CN¥831.94 Million | CN¥121.13 Million | 0.146x | +7.20% |
| 2017-12-31 | CN¥549.27 Million | CN¥74.61 Million | 0.136x | +31.73% |
| 2016-12-31 | CN¥465.47 Million | CN¥48.00 Million | 0.103x | +6.05% |
| 2015-12-31 | CN¥317.41 Million | CN¥30.86 Million | 0.097x | -77.84% |
| 2014-12-31 | CN¥241.57 Million | CN¥105.98 Million | 0.439x | +177.50% |
| 2013-12-31 | CN¥327.59 Million | CN¥51.79 Million | 0.158x | -- |